Pacira Pharma (PCRX) Misses Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results
August 2, 2017 7:30 AM EDT-- EXPAREL® Net Product Sales Up 6% Year-Over-Year ---- Full-year EXPAREL net product sales guidance of $290 to $310 million reiterated ---- Conference Call Today at 8:30 a.m. ET --
PARSIPPANY, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated financial results for the second quarter ended June 30, 2017.
We are pleased to... More



